All articlesPharmaceutical Intermediates

CDI (CAS 530-62-1) in Pharmaceutical Intermediates and API Synthesis

·6 min read

From carbamate linkers to urea-based kinase inhibitors, 1,1′-Carbonyldiimidazole drives some of the most important bond-forming steps in modern API synthesis.

A safer phosgene alternative for API synthesis

1,1′-Carbonyldiimidazole (CDI, CAS 530-62-1) delivers a single carbonyl group between two nucleophiles, making it ideal for constructing carbamate (–OC(O)N–), urea (–NHC(O)NH–), amide, and active-ester functionalities found across modern drug substances.

Unlike phosgene, triphosgene, or carbonyl chlorides, CDI is a free-flowing crystalline solid that can be handled safely on plant scale — reducing capital cost, regulatory burden, and operator exposure risk.

Common API motifs built with CDI

CDI is the reagent of choice for installing high-value functional groups present in oncology, CNS, antiviral, and cardiovascular drug candidates.

  • Ureas in kinase inhibitors (sorafenib-class scaffolds)
  • Carbamate prodrugs and protecting groups (Boc, Cbz analogs)
  • Imidazolide intermediates for macrocyclization
  • Acyl-CoA mimetics and activated esters for biocatalysis
  • Heterocycle formation: oxazolidinones, hydantoins, cyclic ureas

Why CDMOs and API plants standardize on CDI

CDI offers predictable kinetics, low metal contamination, and impurity profiles that translate directly into ICH-compliant filings. Its by-products (imidazole and CO₂) wash out easily during aqueous workup, improving yield and reducing genotoxic impurity risk.

MT Chemtech ships pharmaceutical-grade CDI globally with full COA, MSDS, and regulatory documentation supporting DMF and CEP submissions.

Need bulk 1,1′-Carbonyldiimidazole (CDI), Cas No. 530-62-1?

MT Chemtech is a leading CDI manufacturer shipping pharmaceutical-grade material worldwide. Download our MSDS & COA or request a quote.